JP2019527682A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019527682A5 JP2019527682A5 JP2019500570A JP2019500570A JP2019527682A5 JP 2019527682 A5 JP2019527682 A5 JP 2019527682A5 JP 2019500570 A JP2019500570 A JP 2019500570A JP 2019500570 A JP2019500570 A JP 2019500570A JP 2019527682 A5 JP2019527682 A5 JP 2019527682A5
- Authority
- JP
- Japan
- Prior art keywords
- substituted
- unsubstituted
- alkyl
- pharmaceutically acceptable
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662358524P | 2016-07-05 | 2016-07-05 | |
| US62/358,524 | 2016-07-05 | ||
| PCT/US2017/040722 WO2018009544A1 (en) | 2016-07-05 | 2017-07-05 | Bicyclic urea kinase inhibitors and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019527682A JP2019527682A (ja) | 2019-10-03 |
| JP2019527682A5 true JP2019527682A5 (enExample) | 2020-08-13 |
| JP7277357B2 JP7277357B2 (ja) | 2023-05-18 |
Family
ID=59351134
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019500570A Active JP7277357B2 (ja) | 2016-07-05 | 2017-07-05 | 二環式尿素キナーゼインヒビターおよびそれらの使用 |
Country Status (10)
| Country | Link |
|---|---|
| US (4) | US10954242B2 (enExample) |
| EP (2) | EP3481830B1 (enExample) |
| JP (1) | JP7277357B2 (enExample) |
| KR (1) | KR20190075043A (enExample) |
| CN (1) | CN110225914A (enExample) |
| AU (1) | AU2017291812B2 (enExample) |
| CA (2) | CA3069016A1 (enExample) |
| ES (1) | ES2920823T3 (enExample) |
| IL (1) | IL264106B (enExample) |
| WO (1) | WO2018009544A1 (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10287268B2 (en) | 2014-07-21 | 2019-05-14 | Dana-Farber Cancer Institute, Inc. | Imidazolyl kinase inhibitors and uses thereof |
| AU2017291812B2 (en) * | 2016-07-05 | 2023-12-14 | Dana-Farber Cancer Institute, Inc. | Bicyclic urea kinase inhibitors and uses thereof |
| US11241435B2 (en) | 2016-09-16 | 2022-02-08 | The General Hospital Corporation | Uses of salt-inducible kinase (SIK) inhibitors for treating osteoporosis |
| BR112019017741A2 (pt) * | 2017-02-28 | 2020-04-07 | Dana Farber Cancer Inst Inc | usos de pirimidopirimidinonas como inibidores de sik |
| AU2019243289B2 (en) * | 2018-03-30 | 2023-01-12 | Les Laboratoires Servier | Heterobicyclic inhibitors of MAT2A and methods of use for treating cancer |
| EP3831409A4 (en) * | 2018-08-01 | 2022-05-11 | ONO Pharmaceutical Co., Ltd. | Therapeutic agent for cartilage disease |
| US20230027026A1 (en) * | 2019-09-27 | 2023-01-26 | Jubilant Biosys Limited | Fused pyrimidine compounds, compositions and medicinal applications thereof |
| GB201915828D0 (en) | 2019-10-31 | 2019-12-18 | Cancer Research Tech Ltd | Compounds, compositions and therapeutic uses thereof |
| GB201915829D0 (en) | 2019-10-31 | 2019-12-18 | Cancer Research Tech Ltd | Compounds, compositions and therapeutic uses thereof |
| GB201915831D0 (en) | 2019-10-31 | 2019-12-18 | Cancer Research Tech Ltd | Compounds, compositions and therapeutic uses thereof |
| CN115916966A (zh) * | 2020-01-30 | 2023-04-04 | 加利福尼亚大学董事会 | Strad结合剂及其用途 |
| AU2021262482A1 (en) * | 2020-04-28 | 2023-01-05 | Iomx Therapeutics Ag | Bicyclic kinase inhibitors and uses thereof |
| US12428422B2 (en) | 2020-05-14 | 2025-09-30 | Rhizen Pharmaceuticals Ag | Purine derivatives as SIK-3 inhibitors |
| US12590098B2 (en) | 2020-09-16 | 2026-03-31 | Axceso Biopharma Co., Ltd. | Pyrimido pyrimidinone compound and pharmaceutical composition comprising the same |
| US20230265099A1 (en) * | 2020-09-21 | 2023-08-24 | Soltego, Inc. | Sik inhibitors and methods of use thereof |
| CN116801878A (zh) * | 2020-10-05 | 2023-09-22 | 达纳-法伯癌症研究所股份有限公司 | Her2的有效和选择性抑制剂 |
| US20240124464A1 (en) * | 2020-12-02 | 2024-04-18 | Impact Therapeutics (Shanghai), Inc | Substituted fused bicyclic compound as kinase inhibitor and use thereof |
| US20240100177A1 (en) * | 2020-12-04 | 2024-03-28 | Dyne Therapeutics, Inc. | Antibody-oligonucleotide complexes and uses thereof |
| US20240174662A1 (en) * | 2021-02-01 | 2024-05-30 | Janssen Biotech, Inc. | Small molecule inhibitors of salt inducible kinases |
| KR20230053049A (ko) * | 2021-10-13 | 2023-04-21 | 서울대학교산학협력단 | 류마티스 관절염 예방 또는 치료용 약학적 조성물 및 건강기능식품 |
| CN116813608B (zh) * | 2023-06-08 | 2024-03-22 | 英矽智能科技(上海)有限公司 | 噻唑类化合物及其应用 |
| CN117547615B (zh) * | 2023-09-26 | 2024-12-06 | 首都医科大学宣武医院 | 一种纳米囊泡及其制备方法和应用 |
Family Cites Families (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4231559B2 (ja) | 1997-04-23 | 2009-03-04 | オリザ油化株式会社 | リポキシゲナーゼ阻害剤 |
| EE200000706A (et) | 1998-05-26 | 2002-06-17 | Warner-Lambert Company | Bitsüklilised pürimidiinid ja bitsüklilised 3,4-dihüdropürimidiinid kui rakkude proliferatsiooni inhibiitorid |
| CN1150195C (zh) | 1998-10-23 | 2004-05-19 | 霍夫曼-拉罗奇有限公司 | 双环氮杂环 |
| AU2003225161A1 (en) | 2002-04-24 | 2003-11-10 | Koo, Han-Mo | Enhancement of human epidermal melanogenesis |
| US7084270B2 (en) | 2002-08-14 | 2006-08-01 | Hoffman-La Roche Inc. | Pyrimido compounds having antiproliferative activity |
| DE10239042A1 (de) | 2002-08-21 | 2004-03-04 | Schering Ag | Makrozyclische Pyrimidine, deren Herstellung und Verwendung als Arzneimittel |
| AU2003257633A1 (en) | 2002-08-21 | 2004-03-11 | Mitsuhiro Okamoto | Salt-inducible kinases 2 and use thereof |
| US7112676B2 (en) * | 2002-11-04 | 2006-09-26 | Hoffmann-La Roche Inc. | Pyrimido compounds having antiproliferative activity |
| KR20050084027A (ko) | 2002-11-28 | 2005-08-26 | 쉐링 악티엔게젤샤프트 | Ｃｈｋ-, ｐｄｋ- 및 ａｋｔ-억제성 피리미딘, 그의제조방법 및 약제로서의 그의 용도 |
| JP2006522756A (ja) | 2003-04-10 | 2006-10-05 | エフ．ホフマン−ラ ロシュ アーゲー | ピリミド化合物 |
| US7504396B2 (en) | 2003-06-24 | 2009-03-17 | Amgen Inc. | Substituted heterocyclic compounds and methods of use |
| US7442698B2 (en) | 2003-07-24 | 2008-10-28 | Amgen Inc. | Substituted heterocyclic compounds and methods of use |
| WO2005011597A2 (en) * | 2003-07-29 | 2005-02-10 | Irm Llc | Compounds and compositions as protein kinase inhibitors |
| ES2396135T3 (es) | 2004-06-10 | 2013-02-19 | Irm Llc | Compuestos y composiciones como inhibidores de proteínas cinasas |
| GB0512324D0 (en) | 2005-06-16 | 2005-07-27 | Novartis Ag | Organic compounds |
| JP2008510690A (ja) | 2004-08-31 | 2008-04-10 | エフ．ホフマン−ラ ロシュ アーゲー | ３−フェニル−ジヒドロピリミド［４，５−ｄ］ピリミジノンのアミド誘導体、これらの製造、及び医薬品としての使用 |
| WO2006024545A1 (en) | 2004-09-03 | 2006-03-09 | Stichting Voor De Technische Wetenschappen | Fused bicyclic natural compounds and their use as inhibitors of parp and parp-mediated inflammatory processes |
| CA2590110C (en) | 2004-12-30 | 2014-06-03 | Exelixis, Inc. | Kinase modulators and method of use |
| EP1865959A2 (en) | 2005-03-25 | 2007-12-19 | Glaxo Group Limited | Process for preparing pyridoý2,3-d¨pyrimidin-7-one and 3,4-dihydropyrimidoý4,5-d¨pyrimidin-2(1h)-one derivatives |
| CA2610598A1 (en) * | 2005-06-10 | 2006-12-21 | Irm Llc | Compounds that maintain pluripotency of embryonic stem cells |
| WO2007071752A2 (en) | 2005-12-21 | 2007-06-28 | Novartis Ag | Pyrimidinyl aryl urea derivatives being fgf inhibitors |
| MX2008014618A (es) * | 2006-05-15 | 2008-11-28 | Irm Llc | Composiciones y metodos para inhibidores de cinasas del receptor fgf. |
| WO2008060248A1 (en) | 2006-11-15 | 2008-05-22 | S*Bio Pte Ltd. | Indole sustituted pyrimidines and use thereof in the treatment of cancer |
| ES2734288T3 (es) | 2007-11-28 | 2019-12-05 | Dana Farber Cancer Inst Inc | Inhibidores de miristato de moléculas pequeñas de Bcr-abl y métodos de uso |
| US20100056524A1 (en) | 2008-04-02 | 2010-03-04 | Mciver Edward Giles | Compound |
| WO2009152027A1 (en) | 2008-06-12 | 2009-12-17 | Merck & Co., Inc. | 5,7-dihydro-6h-pyrrolo[2,3-d]pyrimidin-6-one derivatives for mark inhibition |
| EP2320907A4 (en) | 2008-08-05 | 2012-09-05 | Merck Sharp & Dohme | THERAPEUTIC COMPOUNDS |
| US8575179B2 (en) * | 2008-12-12 | 2013-11-05 | Msd K.K. | Dihydropyrazolopyrimidinone derivatives |
| WO2011047119A1 (en) | 2009-10-14 | 2011-04-21 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis c |
| CN102816162B (zh) * | 2011-06-10 | 2016-04-27 | 中国科学院广州生物医药与健康研究院 | 嘧啶并嘧啶酮类化合物及其药用组合物和应用 |
| BR112014007622A2 (pt) | 2011-09-30 | 2017-04-04 | Oncodesign Sa | inibidores de flt3 cinase macrocíclicos |
| WO2013074986A1 (en) | 2011-11-17 | 2013-05-23 | Dana-Farber Cancer Institute, Inc. | Inhibitors of c-jun-n-terminal kinase (jnk) |
| GB201204384D0 (en) | 2012-03-13 | 2012-04-25 | Univ Dundee | Anti-flammatory agents |
| SI3459942T1 (sl) | 2012-04-24 | 2021-05-31 | Vertex Pharmaceuticals Incorporated | Inhibitorji DNA-PK |
| GB201212960D0 (en) * | 2012-07-20 | 2012-09-05 | Common Services Agency | Erythroid production |
| JP5683634B2 (ja) * | 2012-11-28 | 2015-03-11 | 株式会社ショーワ | 圧力緩衝装置 |
| US9260426B2 (en) | 2012-12-14 | 2016-02-16 | Arrien Pharmaceuticals Llc | Substituted 1H-pyrrolo [2, 3-b] pyridine and 1H-pyrazolo [3, 4-b] pyridine derivatives as salt inducible kinase 2 (SIK2) inhibitors |
| WO2014138485A1 (en) * | 2013-03-08 | 2014-09-12 | Irm Llc | Ex vivo production of platelets from hematopoietic stem cells and the product thereof |
| JP6576325B2 (ja) * | 2013-03-15 | 2019-09-18 | セルジーン シーエーアール エルエルシー | ヘテロアリール化合物およびそれらの使用 |
| AU2014230125A1 (en) | 2013-03-15 | 2015-10-29 | Oncodesign S.A. | Macrocyclic salt-inducible kinase inhibitors |
| AU2014287209B2 (en) | 2013-07-09 | 2019-01-24 | Dana-Farber Cancer Institute, Inc. | Kinase inhibitors for the treatment of disease |
| CN104418860B (zh) * | 2013-08-20 | 2016-09-07 | 中国科学院广州生物医药与健康研究院 | 嘧啶并杂环类化合物及其药用组合物和应用 |
| US10287268B2 (en) | 2014-07-21 | 2019-05-14 | Dana-Farber Cancer Institute, Inc. | Imidazolyl kinase inhibitors and uses thereof |
| DK3172213T3 (da) | 2014-07-21 | 2021-12-13 | Dana Farber Cancer Inst Inc | Makrocykliske kinasehæmmere og anvendelser deraf |
| WO2016023014A2 (en) | 2014-08-08 | 2016-02-11 | Dana-Farber Cancer Institute, Inc. | Uses of salt-inducible kinase (sik) inhibitors |
| KR101850282B1 (ko) | 2014-11-26 | 2018-05-31 | 한국과학기술연구원 | 단백질 키나아제 저해제로 유용한 헤테로아릴아민 유도체 |
| CN104482860B (zh) | 2014-12-05 | 2017-10-31 | 浙江大学宁波理工学院 | 鱼类形态参数自动测量装置和方法 |
| AU2017291812B2 (en) * | 2016-07-05 | 2023-12-14 | Dana-Farber Cancer Institute, Inc. | Bicyclic urea kinase inhibitors and uses thereof |
| US11241435B2 (en) | 2016-09-16 | 2022-02-08 | The General Hospital Corporation | Uses of salt-inducible kinase (SIK) inhibitors for treating osteoporosis |
| BR112019017741A2 (pt) * | 2017-02-28 | 2020-04-07 | Dana Farber Cancer Inst Inc | usos de pirimidopirimidinonas como inibidores de sik |
-
2017
- 2017-07-05 AU AU2017291812A patent/AU2017291812B2/en active Active
- 2017-07-05 JP JP2019500570A patent/JP7277357B2/ja active Active
- 2017-07-05 EP EP17740232.8A patent/EP3481830B1/en active Active
- 2017-07-05 EP EP21218204.2A patent/EP4047001A3/en active Pending
- 2017-07-05 ES ES17740232T patent/ES2920823T3/es active Active
- 2017-07-05 CA CA3069016A patent/CA3069016A1/en active Pending
- 2017-07-05 US US16/315,438 patent/US10954242B2/en active Active
- 2017-07-05 CA CA3293479A patent/CA3293479A1/en active Pending
- 2017-07-05 CN CN201780054098.0A patent/CN110225914A/zh active Pending
- 2017-07-05 KR KR1020197003642A patent/KR20190075043A/ko not_active Withdrawn
- 2017-07-05 WO PCT/US2017/040722 patent/WO2018009544A1/en not_active Ceased
-
2019
- 2019-01-06 IL IL264106A patent/IL264106B/en unknown
-
2020
- 2020-11-20 US US16/953,984 patent/US11725011B2/en active Active
-
2023
- 2023-03-27 US US18/126,676 patent/US12398145B2/en active Active
-
2025
- 2025-07-01 US US19/256,657 patent/US20260078126A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018522866A5 (enExample) | ||
| JP6342805B2 (ja) | 置換ピラゾロ［３，４−ｄ］ピリミジンおよびその用途 | |
| JP6806562B2 (ja) | ｅＩＦ２α経路の調節因子 | |
| JP2018522867A5 (enExample) | ||
| EP3704098B1 (en) | Modulators of the integrated stress pathway | |
| JP5576485B2 (ja) | 新生物疾患又は自己免疫疾患を処置するためのプロドラッグとしてのフラザノベンゾイミダゾール | |
| JP2019524883A5 (enExample) | ||
| BR112020008817B1 (pt) | Compostos moduladores da via de estresse integrada referência cruzada a pedidos relacionados | |
| JP2023530231A5 (enExample) | ||
| CA3080948A1 (en) | Modulators of the integrated stress pathway | |
| JP2017502006A5 (enExample) | ||
| JP2018515434A5 (enExample) | ||
| EP3724165B1 (en) | New benzamide derivatives as ppar-gamma modulators | |
| CA3080964A1 (en) | Modulators of the integrated stress pathway | |
| EP4050008A1 (en) | Pyridazinone or pyridazine compound and derivative and pharmaceutical composition thereof | |
| JP2017537940A5 (enExample) | ||
| JP2020534373A5 (enExample) | ||
| JP2015508092A5 (enExample) | ||
| JP2020516616A5 (enExample) | ||
| JP2017537886A5 (enExample) | ||
| JP2017534572A5 (enExample) | ||
| JP2025118609A (ja) | Ｎｕｒｒ１受容体調節因子 | |
| JP2019521964A5 (enExample) | ||
| CA3151776A1 (en) | Heterocyclic amide compound, pharmaceutically acceptable salt thereof, and preparation method therefor and use thereof | |
| US20200009175A1 (en) | Nucleobase analogue derivatives and their applications |